I am pleased to meet you!
I am Natasha Calisi, Recruitment Account Manager for the UK at Syneos Health.
It will be my pleasure to support you in your successful search for a fitting opportunity .
Here at Selling Solutions, we offer innovative promotional and educational resources that deliver customized commercial solutions to the world’s leading healthcare companies so they can focus on what they do best, prevent and treat disease.
The spirit of partnership is critical to success at Selling Solutions. We integrate seamlessly with our clients and do what is best for their success. We’re hungry for growth; ramping up our client-specific and therapeutic areas of expertise quickly. Our vast experience makes us some of the most talented professionals in the industry, but we do check our egos at the door. Self-driven, we’re inspired by tackling challenges and taking ownership to ensure successful execution. We pride ourselves on our custom and creative solutions, requiring us to be flexible and adapt in our dynamic environment.
Get engaged as a commercial Professional and use your knowledge to touch lives of individuals, or you can bring your insight to promising ideas that improve patient outcomes for millions. That’s the power of 22,000 minds working in 110 countries around the world. You’ll make your skills and insights matter more than ever before. Now, you can make a change.
With its leading position in the development of nanobody therapeutics, our customer is focused on the area of orphan drugs.
TTP (Thrombotic Thrombocytopenic Purpura) has no current cure. A rare disease which affects app. 3,800 persons per year in Europe (R. Murrin, J. Murray: Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. In: Blood Reviews)
Our client developed an innovative product which is expected to be the first TTP focused drug on the market with an awaited EMA approval in the first half of 2018.
What is TTP?
TTP is a rare disorder of the blood-coagulation system, causing extensive microscopic clots to form in the small blood vessels throughout the body, resulting in low platelet counts. These small blood clots, called thrombi, can damage many organs including the kidneys, heart, brain, and nervous system. In the era before effective treatment with plasma exchange, the fatality rate was about 90%. (Wikipedia)
How is it cured nowadays?
Currently, it is treated by an exchange transfusion involving removal of the patient's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure must be repeated daily to eliminate the inhibitor and abate the symptoms. (Wikipedia)
How does the new drug work?
Our client's product is a highly potent and selective bivalent anti-vWF (anti-von Willebrand factor) Nanobody. It inhibits the interaction between ultra-large vWF and platelet GpIb-IX-V (a profuse membrane receptor complex originating in megakaryocytes and exclusively functional on the surface of platelets) which plays a crucial role in the pathogenesis of TTP (Wikipedia)
For further information about TTP, please watch this 13 minute clip uploaded by CanadaQBank. It will provide you with the scientific basis, needed to understand the uniqueness of tour clients therapeutic approach.
The new treatment will most probably help to avoid the exchange of blood plasma which is currently seen as the only available way to save a patient's life in most cases. The mortality rate under the current options is about 20% to 30% (http://www.understandingttp.com/de/patient/uber-ttp/).
By joining this team you will play an essential role in the global and local success of our commercial mission. Being a key player in a team of highly committed individuals working together across Europe and sharing the passion for a scientific approach and fulfilling a highly ethical mission. You will be a success-critical factor in our mission of launching the first targeted TTP therapy*. This is an INC Research/ inVentiv Health provided service for a globally leading company with years of proven track record in the development of Nanobody Technology.
Starting with the position of a Commercial Director to lead our sales team in Germany, the UK, Italy and France and an EU Product Manager for ensuring professional marketing in all European countries, we will grow the team by deploying Key Account Managers in different European countries over 2018.
This product will be the first TTP targeting nanobody, developed by an orphan drug specialist with a long record of successfully developed cutting-edge products.
Syneos Health will be fully responsible for the commercialisation of this cutting-edge drug in eleven European countries.
Exciting opportunity to launch an orphan disease product which provided in clinical trials evidence for having the potential to reduce mortality and morbidity of TTP patients.
You will be part of a select group of individuals who are dynamic, passionate and committed to building a strong team that works well together to make a real difference to patients.
The spirit of partnership is critical to success at Syneos Health Selling Solutions. We integrate seamlessly with our clients and do what’s best for their success. We’re hungry for growth; ramping up our client-specific and therapeutic areas of expertise quickly. Our vast experience makes us some of the most talented professionals in the industry, but we check our egos at the door. Self-driven, we’re inspired by tackling challenges and taking ownership to ensure successful execution. We pride ourselves on our custom and creative solutions, requiring us to be flexible and adapt to our dynamic environment.
Syneos Health (Nasdaq:XXX) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance.
10 Bloomsbury Way
Phone: +44 (0) 20 7632 1800